AP2S1 and early-onset autosomal dominant Alzheimer disease: However, a recently developed class of sigma-2 antagonists is able to displace Aβ oligomers from sigma-2 neuronal receptors reducing the Aβ neurotoxic effects and shows promise in the treatment of Alzheimer’s disease (Izzo et al., 2014a; Izzo et al., 2014b).